Jerry Avorn
Impact in
- Family Practice top 0.01%
- Medication Adherence and Compliance
- Geriatrics and Gerontology top 0.01%
- Pharmaceutical Practices and Patient Outcomes
Papers in
-
- Health Systems, Economic Evaluations, Quality of Life 165
- Pharmaceutical Economics and Policy 140
- Pharmacology 86
- Pharmaceutical industry and healthcare 78
- Co-authors
- Sebastian Schneeweiß (95 shared papers)Robert J. Glynn (82 shared papers)Aaron S. Kesselheim (135 shared papers)Stephen B. Soumerai (23 shared papers)Daniel H. Solomon (64 shared papers)Raisa Levin (52 shared papers)Helen Mogun (38 shared papers)Philip S. Wang (31 shared papers)
- Journals
- New England Journal of Medicine (47 papers)JAMA (31 papers)Health Affairs (23 papers)Journal of General Internal Medicine (19 papers)Journal of the American Geriatrics Society (18 papers)
- Partner nations
- United StatesNew ZealandCanada
In The Last Decade
Jerry Avorn
513 papers receiving 36.8k citations
Jerry Avorn's Hit Papers
Peers
Comparison fields: 5 of 202
- Family Practice 4.0k
- Geriatrics and Gerontology 5.4k
- Applied Microbiology and Biotechnology 882
- Economics and Econometrics 11.1k
- Pharmacology 3.2k
Countries citing papers authored by Jerry Avorn
This map shows the geographic impact of Jerry Avorn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerry Avorn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerry Avorn more than expected).
Fields of papers citing papers by Jerry Avorn
This network shows the impact of papers produced by Jerry Avorn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerry Avorn. The network helps show where Jerry Avorn may publish in the future.
Co-authors
The 25 scholars most cited alongside Jerry Avorn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 517 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Variable Selection for Propensity Score Models Hit paper breakdown → | 2006 | 1608 |
| 2 | A review of uses of health care utilization databases for epidemiologic research on therapeutics Hit paper breakdown → | 2005 | 995 |
| 3 | High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data Hit paper breakdown → | 2009 | 845 |
| 4 | A combined comorbidity score predicted mortality in elderly patients better than existing scores Hit paper breakdown → | 2011 | 768 |
| 5 | Improving Drug-Therapy Decisions through Educational Outreach Hit paper breakdown → | 1983 | 697 |
| 6 | Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications Hit paper breakdown → | 2005 | 684 |
| 7 | Self-management Education Programs in Chronic Disease Hit paper breakdown → | 2004 | 562 |
| 8 | Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer Hit paper breakdown → | 2003 | 553 |
| 9 | Persistence of Use of Lipid-Lowering Medications Hit paper breakdown → | 1998 | 548 |
| 10 | A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods Hit paper breakdown → | 2005 | 524 |
| 11 | Full Coverage for Preventive Medications after Myocardial Infarction Hit paper breakdown → | 2011 | 508 |
| 12 | 2000 | 486 | |
| 13 | 2004 | 473 | |
| 14 | Scientific versus commercial sources of influence on the prescribing behavior of physicians Hit paper breakdown → | 1982 | 442 |
| 15 | Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index Hit paper breakdown → | 2017 | 426 |
| 16 | 1991 | 395 | |
| 17 | The High Cost of Prescription Drugs in the United States Hit paper breakdown → | 2016 | 394 |
| 18 | 2004 | 377 | |
| 19 | 1994 | 371 | |
| 20 | 1987 | 337 |
About Jerry Avorn
Jerry Avorn is a scholar working on Economics and Econometrics, Pharmacology, Geriatrics and Gerontology, Pediatrics, Perinatology and Child Health and Cardiology and Cardiovascular Medicine, having authored 517 papers that have together received 38.6k indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (165 papers), Pharmaceutical Economics and Policy (140 papers), Pharmaceutical industry and healthcare (78 papers), Pharmaceutical Practices and Patient Outcomes (72 papers), Pharmaceutical studies and practices (62 papers), Medication Adherence and Compliance (59 papers), Blood Pressure and Hypertension Studies (26 papers) and Advanced Causal Inference Techniques (25 papers). The work is most often cited by research in Family Practice (4.0k citations), Geriatrics and Gerontology (5.4k citations), Applied Microbiology and Biotechnology (882 citations), Economics and Econometrics (11.1k citations) and Pharmacology (3.2k citations). Jerry Avorn has collaborated with scholars based in United States, New Zealand and Canada. Frequent co-authors include Sebastian Schneeweiß, Robert J. Glynn, Aaron S. Kesselheim, Stephen B. Soumerai, Daniel H. Solomon, Raisa Levin, Helen Mogun, Philip S. Wang, Til Stürmer and William H. Shrank. Their work appears in journals such as New England Journal of Medicine, JAMA, Health Affairs, Journal of General Internal Medicine and Journal of the American Geriatrics Society.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.